Apellis Pharmaceuticals Overview
Valuation check: APLS's P/E ratio is 38.71, above the Healthcare sector average of 24.78.
Get informed when a big investor buys or sells
+ Follow38.71
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, APLS shows a P/E ratio of 38.71. That is above the Healthcare sector average of 24.78. Scroll down for historical charts and peer comparison views.
The Healthcare sector average P/E ratio is about 24.78. Apellis Pharmaceuticals is at 38.71, which is higher that average. That is roughly 56.2% above the sector mean. Use the comparison chart on this page to see how APLS stacks up against individual peers as well.
Investors watch APLS's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Apellis Pharmaceuticals's latest reading is 38.71. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has Apellis Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently 38.71) with ownership activity and broader fundamentals.
The Healthcare average P/E ratio is about 24.78, while APLS is at 38.71. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
